ZA200706698B - New pharmaceutical compositions for treatment of thrombosis - Google Patents

New pharmaceutical compositions for treatment of thrombosis

Info

Publication number
ZA200706698B
ZA200706698B ZA200706698A ZA200706698A ZA200706698B ZA 200706698 B ZA200706698 B ZA 200706698B ZA 200706698 A ZA200706698 A ZA 200706698A ZA 200706698 A ZA200706698 A ZA 200706698A ZA 200706698 B ZA200706698 B ZA 200706698B
Authority
ZA
South Africa
Prior art keywords
thrombosis
treatment
pharmaceutical compositions
new pharmaceutical
new
Prior art date
Application number
ZA200706698A
Other languages
English (en)
Inventor
Paul A Reilly
James C Gilbert
Thomas H Mueller
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36423564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200706698(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ZA200706698B publication Critical patent/ZA200706698B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200706698A 2005-03-29 2007-08-13 New pharmaceutical compositions for treatment of thrombosis ZA200706698B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05006711 2005-03-29

Publications (1)

Publication Number Publication Date
ZA200706698B true ZA200706698B (en) 2008-12-31

Family

ID=36423564

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200706698A ZA200706698B (en) 2005-03-29 2007-08-13 New pharmaceutical compositions for treatment of thrombosis

Country Status (19)

Country Link
US (2) US20060222640A1 (enExample)
EP (1) EP1885354A2 (enExample)
JP (1) JP2008534552A (enExample)
KR (1) KR20070116936A (enExample)
CN (1) CN101151030A (enExample)
AR (1) AR056291A1 (enExample)
AU (1) AU2006228600A1 (enExample)
BR (1) BRPI0608656A2 (enExample)
CA (1) CA2602563A1 (enExample)
CL (1) CL2010000395A1 (enExample)
EA (1) EA015122B1 (enExample)
IL (1) IL186267A0 (enExample)
MX (1) MX2007010664A (enExample)
NO (1) NO20074149L (enExample)
NZ (1) NZ562775A (enExample)
TW (1) TW200722089A (enExample)
UA (1) UA92603C2 (enExample)
WO (1) WO2006103206A2 (enExample)
ZA (1) ZA200706698B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906894B1 (en) 2000-07-27 2014-12-09 Thomas N. Thomas Methods for preventing and treating thrombotic disorders
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
IL159273A0 (en) * 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
US20080274166A1 (en) * 2005-06-10 2008-11-06 Transpharma Medical Ltd. Patch for Transdermal Drug Delivery
EP2043632A2 (en) * 2006-07-17 2009-04-08 Boehringer Ingelheim International GmbH New indications for direct thrombin inhibitors
CA2666396A1 (en) * 2006-10-10 2008-04-17 Boehringer Ingelheim International Gmbh Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
EP2211918B1 (en) * 2007-10-29 2017-10-18 Syneron Medical Ltd. Vertical patch drying
WO2010013231A2 (en) * 2008-07-29 2010-02-04 Yeda Research And Development Co. Ltd. Modulation of coagulation factors and effectors of same for control of transplant organ size
CA2735983A1 (en) * 2008-09-10 2010-03-18 Transpharma Medical Ltd. Transdermal delivery of oligosaccharides
MX2011004534A (es) * 2008-11-11 2011-05-24 Boehringer Ingelheim Int Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional.
CN103356614A (zh) * 2008-11-11 2013-10-23 贝林格尔.英格海姆国际有限公司 使用达比加群酯或其盐治疗或预防血栓形成且与常规华法林疗法相比具有改良安全性的方法
JP2013510073A (ja) * 2008-11-11 2013-03-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 従来のワルファリン治療に対して有効性が改善されたダビガトランエテキシレートまたはその塩を使用して血栓症を治療または予防するための方法
US8877710B2 (en) 2008-12-30 2014-11-04 Righospitalet Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
WO2013110354A1 (en) * 2012-01-25 2013-08-01 Université Catholique de Louvain Compositions and methods for cell transplantation
EP2667878B1 (en) * 2011-01-25 2016-03-30 Université Catholique de Louvain Compositions and methods for cell transplantation
CN102250099B (zh) * 2011-05-16 2013-10-16 中国药科大学 一类非肽类抗凝血酶抑制剂、其制法以及医药用途
WO2014001220A1 (en) 2012-06-25 2014-01-03 Boehringer Ingelheim International Gmbh Method for prevention of stroke
EP2722033A1 (en) * 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical Compositions of Dabigatran Free Base
WO2014060561A1 (en) * 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
US20160129047A1 (en) 2013-07-05 2016-05-12 Université Catholique de Louvain Conditioned medium from human adult liver stem cells and its use in the treatment of liver disorders
DE102014108210A1 (de) * 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105250286A (zh) * 2015-11-13 2016-01-20 谭惠娟 一种抗血栓组合物
CN108236612A (zh) * 2016-12-27 2018-07-03 李志忠 用于冠脉介入手术中抗凝的组合产品及其用途
US12251377B2 (en) 2019-03-06 2025-03-18 University Of Rochester Anticoagulant compositions and uses thereof
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use
CN115192691B (zh) * 2022-08-31 2025-03-04 晓恩医药包装材料(安庆)有限公司 一种阿加曲班注射液及预灌封注射器

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
NZ286082A (en) * 1995-03-15 1998-09-24 Behringwerke Ag Method of treating acute myocardial infarction with hirudin and acetylsalicylic acid in patients not undergoing thrombolytic treatment
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6414008B1 (en) * 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
DE19834751A1 (de) * 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9930540D0 (en) * 1999-12-23 2000-02-16 Rhone Poulenc Rorer Pharma Chemical compounds
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
US8183206B2 (en) * 2001-09-14 2012-05-22 Mitsubishi Tanabe Pharma Corporation Drugs comprising combination of antithrombotic agent with pyrazolone derivative
IL163863A0 (en) * 2002-03-07 2005-12-18 Boehringer Sohn Ingelheim Form of presentation for3-Ä(2-äÄ4-(hexyloxycarbonylamino-imino-methyl)-phenylaminoÜmethylü-1-methyl-1H-benzimidaz
DE10235639A1 (de) * 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
BRPI0409796A (pt) * 2003-04-24 2006-05-30 Boehringer Ingelheim Int uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina

Also Published As

Publication number Publication date
NO20074149L (no) 2007-12-11
IL186267A0 (en) 2008-01-20
NZ562775A (en) 2011-03-31
AR056291A1 (es) 2007-10-03
TW200722089A (en) 2007-06-16
MX2007010664A (es) 2007-12-12
CA2602563A1 (en) 2006-10-05
JP2008534552A (ja) 2008-08-28
US20100184729A1 (en) 2010-07-22
CL2010000395A1 (es) 2010-08-20
US20060222640A1 (en) 2006-10-05
KR20070116936A (ko) 2007-12-11
BRPI0608656A2 (pt) 2010-01-19
AU2006228600A1 (en) 2006-10-05
WO2006103206A2 (en) 2006-10-05
UA92603C2 (ru) 2010-11-25
EA015122B1 (ru) 2011-06-30
CN101151030A (zh) 2008-03-26
EA200701841A1 (ru) 2008-02-28
WO2006103206A3 (en) 2007-01-11
EP1885354A2 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
ZA200706698B (en) New pharmaceutical compositions for treatment of thrombosis
IL268462A (en) Dosage form of risedronate
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
IL186578A0 (en) Compositions for treatment of neovascularization diseases
TWI369987B (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
EP1871331A4 (en) COMPOSITION FOR THE TREATMENT OF MENOPAUSE
ZA200802762B (en) Pharmaceutical compositions for the treatment of inner ear disorders
IL245513A0 (en) Medical preparations containing ingenol-3-angelate
IL186808A0 (en) Topiramate compositions for treatment of headache
IL190779A0 (en) Compositions for treatment of eye diseases
IL186989A0 (en) Therapeutic compositions
IL189614A0 (en) Pharmaceutical compositions of telmisartan
EP1938842A4 (en) METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS
EP2213303A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT
EP1871363A4 (en) COMBINED STAGE PROCESS FOR PHARMACEUTICAL COMPOSITIONS
IL183893A0 (en) Pharmaceutical compositions for the treatment of cellulite
EP2114374A4 (en) PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE
GB0619500D0 (en) Treatment of fibrosis
IL179337A0 (en) Pharmaceutical compositions for the treatment of pruritus
IL194066A0 (en) Therapeutic composition for treatment of tinnitus
GB0605715D0 (en) Treatment of laminitis
HU0500145D0 (en) Composition for the treatment of oral diseases
HUP0500947A2 (en) Composition for treatment of paradontosis
HUP0500685A2 (en) Pharmaceutical composition for the treatment of psychosis
HU0501084D0 (en) New pharmaceutical compositions of high effectivity